What is Nvigen?
NVIGEN is a biotechnology firm at the vanguard of personalized medicine, specializing in advanced assays that unify DNA, RNA, protein, and cell information. Leveraging molecularly engineered nanoparticles, NVIGEN offers innovative solutions like the NVIGEN X Cancer Precision Profiling Test and MagVigen nanoparticles. These tools are engineered for the biotech community to advance cancer detection, monitoring, and therapeutic strategies. The company's core mission is to drive progress in biomarker profiling, precision diagnostics, and T-cell therapy, addressing critical health challenges including aging, cancer, and cardiovascular diseases. NVIGEN's dedication to pioneering research and collaborative efforts aims to equip healthcare professionals with efficient and effective solutions.
How much funding has Nvigen raised?
Nvigen has raised a total of $1.2M across 2 funding rounds:
Series B
$1.1M
Debt
$53K
Series B (2014): $1.1M, investors not publicly disclosed
Debt (2021): $53K led by PPP
What's next for Nvigen?
With the recent substantial expansion capital, NVIGEN is poised for significant scaling and further development of its proprietary nanoparticle technology. This strategic investment is expected to accelerate the commercialization of its precision profiling tests and broaden its market reach within the oncology and diagnostics sectors. The company's focus on integrating multi-omic data through its unique nanoparticle platform positions it for leadership in precision medicine, potentially enabling more targeted therapies and improved patient outcomes. Future endeavors will likely involve expanding clinical validation, forging strategic partnerships, and enhancing its product pipeline to address a wider spectrum of complex diseases.
See full Nvigen company page
